



RECEIVED

JUN 27 2003

1615

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicants: Michel Pairet *et al.*

Examiner: Humera Sheikh

Serial No.: 10/007,182

Group Art Unit: 1615

Filed: October 19, 2001

Docket: 1/1244

RECEIVED

#10/A
AKO
7-10-03

For: PHARMACEUTICAL COMPOSITIONS CONTAINING TIOTROPIUM SALTS AND ANTIHISTAMINES AND THEIR USE

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 C.F.R. § 1.111
IN RESPONSE TO APRIL 9, 2003, OFFICE ACTION

Sir:

This Amendment is filed in response to the Office Action dated April 9, 2003. In that Office Action, a three month shortened statutory period was set for response, and this Amendment is therefore timely. If it is determined that any fees under 37 C.F.R. §§ 1.16 or 1.17 are due in connection with this Amendment, however, authorization is hereby given to charge such fees to Deposit Account No. 02-2955.

Please amend the application as follows.

In the Claims

In accordance with 37 C.F.R. § 1.121(c), please cancel claims 10 to 16 and 26 to 32 and amend claims 1, 17 to 25, 54, and 55 as follows (the marked up version of the amended claims follows the Remarks).

--1. (Amended) An inhalable powder pharmaceutical composition comprising:

- (a) a tiotropium salt;
- (b) an antihistamine; and
- (c) a pharmaceutically acceptable excipient selected from glucose, arabinose, lactose, saccharose, or maltose,

the tiotropium salt and the antihistamine optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates.--